Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Management of recurrent Ewing sarcoma: challenges and approaches.

Van Mater D, Wagner L.

Onco Targets Ther. 2019 Mar 27;12:2279-2288. doi: 10.2147/OTT.S170585. eCollection 2019. Review.

2.

Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution.

Farhat R, Raad R, Khoury NJ, Feghaly J, Eid T, Muwakkit S, Abboud M, El-Solh H, Saab R.

J Pediatr Hematol Oncol. 2013 Jul;35(5):356-60. doi: 10.1097/MPH.0b013e318270a343.

PMID:
23042020
3.

[Chemotherapy in patients with refractory Ewing sarcoma].

Raciborska A, Bilska K, Drabko K, Rogowska E, Chaber R, Pogorzała M, Wyrobek E, Połczyńska K, Rodriguez-Galindo C, Woźniak W.

Med Wieku Rozwoj. 2013 Apr-Jun;17(2):117-25. Polish.

4.

Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.

Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M, Poos K, Korsching E, Buch T, Weckesser M, Schulze I, Besoke R, Witten A, Stoll M, Köhler G, Hartmann W, Wardelmann E, Rossig C, Baumhoer D, Jürgens H, Burdach S, Berdel WE, Müller-Tidow C.

Clin Cancer Res. 2015 Nov 1;21(21):4935-46. doi: 10.1158/1078-0432.CCR-14-2744. Epub 2015 Jul 15.

5.

Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

Mascarenhas L, Felgenhauer JL, Bond MC, Villaluna D, Femino JD, Laack NN, Ranganathan S, Meyer J, Womer RB, Gorlick R, Krailo MD, Marina N.

Pediatr Blood Cancer. 2016 Mar;63(3):493-8. doi: 10.1002/pbc.25837. Epub 2015 Nov 18.

6.

Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.

Wagner L.

Sarcoma. 2011;2011:957957. doi: 10.1155/2011/957957. Epub 2011 Apr 6.

7.

Long-term Outcomes and Complications in Pediatric Ewing Sarcoma.

Hamilton SN, Carlson R, Hasan H, Rassekh SR, Goddard K.

Am J Clin Oncol. 2017 Aug;40(4):423-428. doi: 10.1097/COC.0000000000000176.

PMID:
25599318
8.

Systemic therapy for osteosarcoma and Ewing sarcoma.

Meyers PA.

Am Soc Clin Oncol Educ Book. 2015:e644-7. doi: 10.14694/EdBook_AM.2015.35.e644. Review.

9.
10.

Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.

van Maldegem AM, Benson C, Rutkowski P, Blay JY, van den Berg H, Placzke J, Rasper M, Judson I, Juergens H, Dirksen U, Gelderblom H.

Pediatr Blood Cancer. 2015 Jan;62(1):40-4. doi: 10.1002/pbc.25230. Epub 2014 Sep 22.

PMID:
25251256
11.

Clinical outcomes of adult patients with relapsed Ewing sarcoma: a 30-year single-institution experience.

Robinson SI, Ahmed SK, Okuno SH, Arndt CA, Rose PS, Laack NN.

Am J Clin Oncol. 2014 Dec;37(6):585-91. doi: 10.1097/COC.0b013e318281d6ab.

PMID:
23466580
12.

Optimal management strategies for rhabdomyosarcoma in children.

Walterhouse D, Watson A.

Paediatr Drugs. 2007;9(6):391-400. Review.

PMID:
18052409
13.

Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.

Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E, Rodriguez-Galindo C, Wozniak W.

Pediatr Blood Cancer. 2013 Oct;60(10):1621-5. doi: 10.1002/pbc.24621. Epub 2013 Jun 15.

PMID:
23776128
14.

Patient-Reported Functional and Quality of Life Outcomes in a Large Cohort of Long-Term Survivors of Ewing Sarcoma.

Stish BJ, Ahmed SK, Rose PS, Arndt CA, Laack NN.

Pediatr Blood Cancer. 2015 Dec;62(12):2189-96. doi: 10.1002/pbc.25710. Epub 2015 Aug 14.

15.

A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study.

Morland B, Platt K, Whelan JS.

Pediatr Blood Cancer. 2014 Mar;61(3):442-5. doi: 10.1002/pbc.24767. Epub 2013 Sep 9.

PMID:
24019263
16.

Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients.

Youn P, Milano MT, Constine LS, Travis LB.

Cancer. 2014 Aug 1;120(15):2334-42. doi: 10.1002/cncr.28733. Epub 2014 Apr 18.

17.

A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.

Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E.

Pediatr Hematol Oncol. 2013 Apr;30(3):170-7. doi: 10.3109/08880018.2013.767868.

PMID:
23484903
18.

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.

Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA.

Pediatr Blood Cancer. 2009 Dec;53(6):1029-34. doi: 10.1002/pbc.22206.

PMID:
19637327
19.

Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).

Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C.

Cancer. 2012 Oct 15;118(20):5050-9. doi: 10.1002/cncr.27493. Epub 2012 Mar 13.

20.

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H.

Pediatr Blood Cancer. 2006 Nov;47(6):795-800.

PMID:
16411206

Supplemental Content

Support Center